• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

    1.770 -0.090 (-4.84%)
    Streaming Delayed Price Updated: 1:06 PM EDT, Apr 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Acrivon Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Registration Momentum Builds Across the Oncology Pipeline
    Issued on behalf of Oncolytics Biotech Inc. 
    From USA News Group
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
    Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, will highlight company’s recent interim clinical data from the ongoing,... 
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    On Friday, there are stocks with unusual volume. Let's take a look. ↗
    Via Chartmill
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
    Via Chartmill
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    News headline image
    Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
    Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    Let's have a look at the stocks with an unusual volume in today's session. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Friday's after hours session: top gainers and losers ↗
    After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
    Via Chartmill
    News headline image
    Acrivon Posts Narrower Loss in Q2 ↗
    Via The Motley Fool
    News headline image
    Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.